Skip to main content

Venture capital fund AmorChem announces support of a project in Jasna Kriz’s laboratory


AmorChem recently announced the financing of a project in the laboratory of Jasna Kriz which aims to develop new therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS) and other neuroinflammatory diseases.  Following an agreement between Université Laval and the CERVO Brain Research Centre (CIUSSS-CN), the venture capital fund AmorChem will invest in a project which targets a molecule, called SRSF3, which is involved in regulation of innate immunity. 



“The past few years have confirmed the promise of therapeutic strategies focusing on innate immunity. This project allows AmorChem to work on a target that plays a key role in its control. This mechanism of action is very relevant for neuroinflammatory diseases, most notably for amyotrophic lateral sclerosis”, says Elizabeth Douville, PhD, co-founder and managing partner at AmorChem.





Read an article in the Financial Post about this important agreement.





AmorChem Reinforces Its Innate Immunity Franchise with an Investment in Checkpoint Control Target SRSF3